arrow
J

Jessica Maitland

johnson & johnson usa
H指数:8
被引数:542

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-World Evidence of Treatment Patterns, Time to Real-World Progression, and Overall Survival of Patients With Testicular Germ Cell Tumors Receiving Palliative Chemotherapy in the United States

美国接受姑息化疗的睾丸生殖细胞肿瘤患者的治疗模式、达到真实世界进展的时间和总生存期的真实世界证据

2026-06-110
OAAI
Real-World Incidence and Management of Non-Immune Effector Cell-Associated Neurotoxicity Syndrome Neurologic Events Following Ciltacabtagene Autoleucel in Multiple Myeloma

真实世界中,Ciltacabtagene Autoleucel治疗多发性骨髓瘤后非免疫效应细胞相关神经毒性综合征神经事件的发病情况与管理

2026-05-270
OAAI
Real-world healthcare resource utilization and clinical outcomes among patients with relapsed/refractory multiple myeloma receiving ciltacabtagene autoleucel after four or more prior lines of therapy in inpatient versus outpatient settings

住院与门诊环境中,接受至少四线治疗后使用cilta-cabtagene autoleucel的复发/难治性多发性骨髓瘤患者的实际医疗资源利用和临床结局

2026-05-230
PRE
Real-World Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US Databases

真实世界中接受Ciltacabtagene autoleucel治疗的复发或难治性多发性骨髓瘤患者中非ICANS神经事件的大规模美国数据库描述

2026-04-180
OAAI
Clinical outcomes with ciltacabtagene autoleucel among patients with relapsed/refractory multiple myeloma after four or more prior lines of therapy overall and among subgroups based on age, frailty, and CRAB symptoms

在既往接受四种或以上治疗方案的患者中,基于年龄、虚弱程度和CRAB症状的亚组中,ciltacabtagene autoleucel治疗复发性/难治性多发性骨髓瘤的临床结局

2026-02-010
OAAI